Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

1137 - Real-life efficacy of an epoetin alfa biosimilar in chemotherapy-induced anemia


21 Dec 2015


Supportive and palliative care


Florian Scotté


Annals of Oncology (2015) 26 (suppl_9): 111-124. 10.1093/annonc/mdv531


F. Scotté1, K. Laribi2, C. Gisselbrecht3, D. Spaeth4, E. Kasdaghli5, E. Leutenegger6, I. Ray-Coquard7, H. Albrand5

Author affiliations

  • 1 Medical Oncology And Supportive Care Unit, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Department Of Haematology, Centre Hospitalier Du Mans, Le Mans/FR
  • 3 Haematology-oncology Department, Hôpital St. Louis, Paris/FR
  • 4 Oncology Department, Centre d'Oncologie de Gentilly, Nancy/FR
  • 5 Hospira, Hospira France, Meudon La Forêt/FR
  • 6 Epidemiology Department, GECEM, Paris/FR
  • 7 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR

Abstract 1137


The management of chemotherapy-induced anemia (CIA) by erythropoiesis-stimulating agents (ESA) is well established and recommendations are clear on their use. The SYNERGY study aimed to assess the effect of epoetin alfa biosimilar on CIA in current practice.


This observational, longitudinal, prospective, multicenter study was conducted in France, from a representative, random sample of oncologists and hematologists. The primary objective was response to epoetin alfa biosimilar (achieving target Hb level with increase of ≥1 g/dL versus baseline or increase of ≥2 g/dL in the absence of a transfusion in the 3 previous weeks). Data on patient characteristics, cancer diagnosis, methods of epoetin alfa biosimilar and iron use, anemia and iron status assessment were collected on enrollment. The study included patients aged ≥18 years with CIA, with solid tumors (ST), lymphoma or myeloma, eligible for treatment with epoetin alfa biosimilar, with follow-up at 12–16 weeks.


Oncologists and hematologists (n = 195) enrolled 2167 patients between June 2012 and December 2014; 2076 patients (49.4% male) were analyzed. Patient characteristics are shown in the table. Epoetin alfa biosimilar was administered subcutaneously (99.2% of patients) in a single weekly dose of 20,000–40,000 IU for a median duration of 11.0 weeks.

Characteristic Patients (%)
ST (metastatic) 79.8 (72.3)
Lymphoma 12.7
Myeloma 6.6
Mean Hb level, g/dL 9.6
Moderate anemia (8–9.5 g/dL) 37.2
Severe anemia (<8 g/dL) 1.2
Iron status assessment 51.7
Iron supplementation 31.6

At follow-up, 71.9% of patients had a maximum Hb level above 11 g/dL. The mean change ± SD in Hb level was 2.25 ± 1.39 g/dL at its maximum and 1.67 ± 1.55 g/dL at final visit. The overall response rate to epoetin alfa biosimilar was 70.4%; 68.6% for ST; 74.4% for lymphomas, and 81.3% for myelomas. Hb levels increased by ≥2 g/dL in 57.3% and by 1–2 g/dL in 26.4% of patients. Treatment-related adverse events occurred in 3.4% of patients, mainly thromboembolic events (2.0%). The rate of blood transfusions was 16.3%.


These results provide real-life evidence that epoetin alfa biosimilar was effective and well tolerated in treating CIA, and was used in accordance with recommendations.

Clinical trial identification



F. Scotté, K. Laribi, D. Spaeth: grant and/or research support from Hospira SAS

DE. Kasdaghli, H. Albrand: employee of Hospira. E. Leutenegger: employee of GECEM. I. Ray-Coquard: grant and/or research support from Hospira SAS, consultancy fees from Amgen, PharmaMar, Roche, and paid instructor for Amgen, PharmaMar, and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings